Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6109)
All Articles published online
|
Publishing Process of This Article
|
Dec 18, 2016 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol 2016; 8(35): 1541-1546 [PMID: 28050234 DOI: 10.4254/wjh.v8.i35.1541] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v8/i35/1541.htm |
| Number | Citing Articles |
| 1 |
Alice Boilève, Marc Hilmi, Matthieu Delaye, Annemilaï Tijeras-Raballand, Cindy Neuzillet. Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. Cancers 2021; 13(11): 2708 doi: 10.3390/cancers13112708
|
| 2 |
Jean-Luc Raoul, Masatoshi Kudo, Richard S. Finn, Julien Edeline, Maria Reig, Peter R. Galle. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews 2018; 68: 16 doi: 10.1016/j.ctrv.2018.05.006
|
| 3 |
Cindy Neuzillet, Louis de Mestier, Benoît Rousseau, Olivier Mir, Mohamed Hebbar, Hemant M. Kocher, Philippe Ruszniewski, Christophe Tournigand. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacology & Therapeutics 2018; 181: 49 doi: 10.1016/j.pharmthera.2017.07.006
|
| 4 |
Jingyu Chen, Chien-Yu Chen, Christopher Nguyen, Lulu Chen, Kangmin Lee, Bangyan L. Stiles. Emerging signals regulating liver tumor initiating cells. Liver Research 2018; 2(2): 73 doi: 10.1016/j.livres.2018.08.003
|
| 5 |
Carolien M Beukhof, Leni van Doorn, Theo J Visser, Sander Bins, W Edward Visser, Ramona van Heerebeek, Folkert J van Kemenade, Yolanda B de Rijke, Wouter W de Herder, Layal Chaker, Ron H Mathijssen, Robin P Peeters. Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. The Journal of Clinical Endocrinology & Metabolism 2017; 102(8): 2922 doi: 10.1210/jc.2016-4025
|
| 6 |
Cassia Regina Guedes Leal, Cristiane Magalhães, Daniel Barbosa, Diogo Aquino, Bernardo Carvalho, Elizabeth Balbi, Lucio Pacheco, Renata Perez, Paulo de Tarso Pinto, Sérgio Setubal. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Investigational New Drugs 2018; 36(5): 911 doi: 10.1007/s10637-018-0621-x
|
| 7 |
Marc Hilmi, Cindy Neuzillet, Julien Calderaro, Fouad Lafdil, Jean-Michel Pawlotsky, Benoit Rousseau. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. Journal for ImmunoTherapy of Cancer 2019; 7(1) doi: 10.1186/s40425-019-0824-5
|